首页> 外文期刊>BMC Cancer >D-dimer levels and cerebral infarction in critically ill cancer patients
【24h】

D-dimer levels and cerebral infarction in critically ill cancer patients

机译:重症癌症患者的D-二聚体水平和脑梗死

获取原文
           

摘要

Background D-dimer levels have been used in the diagnosis of a variety of thrombosis-related diseases. In this study, we evaluated whether measuring D-dimer levels can help to diagnose cerebral infarction (CI) in critically ill cancer patients. Methods We retrospectively evaluated all cancer patients who underwent brain magnetic resonance imaging (MRI) between March 2010 and February 2014 at the medical oncology intensive care unit (ICU) of Samsung Medical Center. Brain MRI scanning was performed when CI was suspected due to acute neurological deficits. We compared D-dimer levels between patients ultimately diagnosed as having or not having CI and analyzed diffusion-weighted imaging (DWI) lesion patterns. Results A total of 88 patients underwent brain MRI scanning due to clinical suspicion of CI; altered mental status and unilateral hemiparesis were the most common neurological deficits. CI was ultimately diagnosed in 43 (49%) patients. According to the DWI patterns, multiple arterial infarctions (40%) were more common than single arterial infarctions (9%). Cryptogenic stroke etiologies were more common (63%) than determined etiologies. There was no significant difference in D-dimer levels between patients with and without CI ( P =?0.319). Although D-dimer levels were not helpful in diagnosing CI, D-dimer levels were associated with cryptogenic etiologies in critically ill cancer patients; D-dimer levels were higher in the cryptogenic etiology group than in the determined etiology group or the non-infarction group ( P =?0.001). In multivariate analysis, elevated D-dimer levels (> 8.89?μg/mL) were only associated with cryptogenic stroke (adjusted OR 5.46; 95% confidence interval, 1.876–15.857). Conclusions Abnormal D-dimer levels may support the diagnosis of cryptogenic stroke in critically ill cancer patients.
机译:背景D-二聚体水平已用于诊断多种血栓形成相关疾病。在这项研究中,我们评估了测量D-二聚体水平是否可以帮助诊断重症癌症患者的脑梗死(CI)。方法我们回顾性评估了2010年3月至2014年2月在三星医学中心的肿瘤内科重症监护病房(ICU)进行了脑磁共振成像(MRI)的所有癌症患者。当怀疑由于急性神经功能缺损而怀疑CI时,进行脑MRI扫描。我们比较了最终诊断为患有或未患有CI的患者之间的D-二聚体水平,并分析了弥散加权成像(DWI)病变模式。结果由于临床怀疑CI,共有88例患者接受了脑部MRI扫描;精神状态改变和单侧偏瘫是最常见的神经系统缺陷。最终在43名(49%)患者中诊断出CI。根据DWI模式,多发性动脉梗塞(40%)比单发性动脉梗塞(9%)更常见。隐源性卒中病因比确定的病因更为普遍(63%)。有和没有CI的患者之间的D-二聚体水平没有显着差异(P =?0.319)。尽管D-二聚体水平对诊断CI没有帮助,但D-二聚体水平与重症癌症患者的隐源性病因有关。隐源性病因学组的D-二聚体水平高于确定的病因学组或非梗死组(P = 0.001)。在多变量分析中,升高的D-二聚体水平(> 8.89?μg/ mL)仅与隐源性卒中相关(调整后OR为5.46; 95%置信区间为1.876–15.857)。结论D-二聚体水平异常可能支持重症癌症患者的隐源性中风的诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号